Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of ABBV-011 Alone and With Budigalimab in Relapsed/Refractory Small Cell Lung Cancer
jRCT2051200161Phase 1Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 1, open-label trial of ABBV-011 and budigalimab in small cell lung cancer (SCLC) (4 arms), sponsored by AbbVie Inc. Primary endpoints: Number of participants with adverse events, Maximum tolerated dose (MTD) and/or recommended phase 2 dose (RPTD) of ABBV-011 and 5 more. Started Jun 2021; status: active, not recruiting.
02
Drugs
ABBV-011budigalimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCT2051200161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051200161.